Last Updated: August 3, 2026

ZYFLO CR Drug Patent Profile

✉ Email this page to a colleague

When do Zyflo Cr patents expire, and what generic alternatives are available?

Zyflo Cr is a drug marketed by Chiesi and is included in one NDA.

The generic ingredient in ZYFLO CR is zileuton. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the zileuton profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zyflo Cr

A generic version of ZYFLO CR was approved as zileuton by RISING on March 17^th, 2017.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ZYFLO CR?
What are the global sales for ZYFLO CR?
What is Average Wholesale Price for ZYFLO CR?

Summary for ZYFLO CR

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZYFLO CR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	ZYFLO CR	zileuton	TABLET, EXTENDED RELEASE;ORAL	022052-001	May 30, 2007		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ZYFLO CR

See the table below for patents covering ZYFLO CR around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Austria	147383		⤷ Start Trial
Australia	1143388		⤷ Start Trial
Australia	608804		⤷ Start Trial
Australia	6220190		⤷ Start Trial
Australia	631244		⤷ Start Trial
Canada	1306744	COMPOSES INHIBANT LA LIPOGENASE CONTENANT DE L'INDOLE, DU BENZOFURANE ET DU BENZOTHIOPHENE (INDOLE, BENZOFURAN, BENZOTHIOPHENE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS)	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.